Tern raises £222,000 through share placing

TERN

Tern Plc (LON:TERN), the Company focused on value creation from Internet of Things (IoT) technology businesses, has announced that it has raised £222,000, before expenses, through a placing of 37,000,000 new ordinary shares of 0.02p each in the Company at a price of 0.60 pence per new Ordinary Share. The Placing is conditional upon the Placing Shares being admitted to trading on AIM.

The Placing, conducted at the same Issue Price as the Open Offer that completed on 14 May 2026, utilises substantially all of the Tern Director’s remaining authority to allot new Ordinary Shares granted at the Company’s General Meeting held on 8 May 2026 and is for an amount of Ordinary Shares marginally less than the number of Open Offer Shares not subscribed for by Qualifying Shareholders in the Open Offer.

The net proceeds of the Placing are intended to be used towards the same purposes outlined in the Company’s Circular and announcement of 21 April 2026 in relation to the Open Offer. Further announcements are expected to be made in due course in relation to the application of the net proceeds of the Placing and the Open Offer.

CMC Markets UK Plc trading as CMC CapX, acted as the Company’s sole placing agent in respect of the Placing.

Admission and Total Voting Rights

The Placing Shares will rank pari passu in all respects with the Company’s existing issued Ordinary Shares. The Placing is conditional, inter alia, on: i) there being no breach of the obligations under the Placing Agreement entered into between CMC Markets and the Company prior to Admission; and ii) Admission. Application has been made to the London Stock Exchange for the Placing Shares to be admitted to trading on AIM. It is expected that Admission will become effective and that dealings in the Placing Shares on AIM will commence on or around 22 May 2026.

In accordance with the Financial Conduct Authority’s Disclosure, Guidance and Transparency Rules, the Company confirms that following Admission, the Company’s enlarged issued ordinary share capital will comprise 855,543,681 Ordinary Shares. The Company does not hold any shares in Treasury.  Therefore, from Admission, the total number of voting rights in the Company will be 855,543,681 and this figure may be used by shareholders in the Company as the denominator for the calculations to determine if they are required to notify their interest in, or a change to their interest in the Company, under the Disclosure Guidance and Transparency Rules.

Capitalised terms used but not otherwise defined in this announcement bear the meanings ascribed to them in the circular posted to shareholders on 21 April 2026.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

What HCPs say could reveal prescribing intent

Talking Medicines is using AI to analyse HCP conversations and identify the clinical and practical factors that may influence prescribing intent.

AI control of machines raises new security questions

AI is gaining the ability to control physical equipment, but establishing that machines are genuine, authorised and secure will be an important part of making this technology safe to deploy.

CAR-T therapy brings new approach to multiple myeloma treatment

CAR-T therapy is being used in multiple myeloma and is being studied earlier in the treatment pathway, with research focused on improving durability, safety and access.

Tern cuts H1 loss by 60% as portfolio growth and funding strengthen

Tern reduced its first-half loss by 60%, with net asset value improving and further fundraising strengthening the balance sheet. Additional funding has supported Talking Medicines and Device Authority, while continued progress across the portfolio provides further scope for value creation.

AI control of machines creates a new market for device trust

AI is beginning to control physical machines, increasing demand for technology that can verify device identity before those machines are allowed to act.

Peptide drug development expands beyond GLP-1

GLP-1 success is widening interest in peptide drug development, with the next phase focused on proving clinical value across new therapeutic areas.

Search